Sexually transmitted disease

most common cause of curable sexually transmitted infection

Gardnerella vaginalis is a type of bacteria that is commonly found in the vaginal flora of some women. While it can be present in the vagina without causing any issues, it is often associated with bacterial vaginosis (BV), a condition that occurs when the natural balance of bacteria in the vagina is disrupted. BV can lead to symptoms such as unusual discharge, a fishy odor, and vaginal irritation, although some women may not experience any symptoms. Gardnerella vaginalis plays a key role in this imbalance because its overgrowth can reduce the number of "good" bacteria like lactobacilli, which normally help maintain a healthy vaginal environment. BV is not considered a sexually transmitted infection (STI), but it is more common in sexually active women. It is usually treated with antibiotics to restore the normal bacterial balance. -------------------------- Gardnerella vaginalis is a key bacterium associated with bacterial vaginosis (BV), a common vaginal condition characterized by an imbalance in the vaginal microbiome. The presence of G. vaginalis can serve as a biomarker for BV, but its role is complex and nuanced. G. vaginalis as a Biomarker Prevalence and Detection G. vaginalis is found in 95% to 100% of BV cases, making it a highly sensitive biomarker for the condition. However, it's important to note that G. vaginalis can also be present in healthy vaginal microbiomes, albeit in much lower concentrations. Detection methods for G. vaginalis include 16S rRNA gene sequencing and culture-based studies, with some variations in relative levels depending on the specific gene regions targeted. Specificity Considerations While G. vaginalis is highly prevalent in BV, its presence alone is not always indicative of the condition. Colonization by G. vaginalis does not necessarily lead to BV, as some women without BV may have low levels of the bacterium. This suggests that the abundance and potentially the specific strains of G. vaginalis may be more relevant as biomarkers than mere presence. Associated Metabolites GHB Production Recent research has identified γ-hydroxybutyrate (GHB) as a highly specific biomarker associated with G. vaginalis. Studies have demonstrated that G. vaginalis is likely the primary source of GHB detected in vivo, with the bacterium possessing a putative GHB dehydrogenase gene. This metabolite could serve as an indirect biomarker for G. vaginalis presence and activity. Other Metabolic Markers In addition to GHB, other metabolites such as 2-hydroxyisovalerate (2HV) have been identified as sensitive and specific biomarkers for BV, with G. vaginalis likely playing a role in their production. Clinical Significance Diagnostic Potential The combination of G. vaginalis detection with specific metabolite markers like GHB and 2HV shows promise for improving BV diagnosis. In one study, the ratio of 2HV to tyrosine achieved an area under the curve of 0.993 in predicting clinical BV. Epithelial Impact G. vaginalis has been shown to significantly impact cervico-vaginal epithelial function, including increased cell death and decreased barrier integrity. These effects, not observed with beneficial bacteria like Lactobacillus crispatus, could potentially serve as indirect biomarkers of G. vaginalis activity. Future Directions Strain-Specific Biomarkers Recent taxonomic updates have identified multiple species within the Gardnerella genus, suggesting that strain-specific biomarkers may be necessary for more accurate diagnostics. Future research may focus on identifying biomarkers that can differentiate between more and less virulent strains of Gardnerella. Multispecies Interactions Given the complex nature of the vaginal microbiome, future biomarker development may need to consider the interactions between G. vaginalis and other bacterial species, as well as host factors, to improve diagnostic accuracy and predict clinical outcomes.In conclusion, while the presence of G. vaginalis serves as an important biomarker for BV, its interpretation requires consideration of abundance, associated metabolites, and the overall vaginal microbiome context. Ongoing research continues to refine our understanding of G. vaginalis as a biomarker and its role in vaginal health and disease.

AIDS is caused by 2 known types of HIV. HIV type 1 (HIV-1) is found in patients with AIDS or AIDS-related complex and in asymptomatic infected individuals at high risk for AIDS. The virus is transmitted by sexual contact, by exposure to infected blood or blood products, or from an infected mother to her fetus or infant. HIV type 2 (HIV-2) infection is endemic only in West Africa, and it has been identified in individuals who had sexual relations with individuals from that geographic region. HIV-2 is similar to HIV-1 in viral morphology, overall genomic structure, and its ability to cause AIDS. Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure and are almost always detectable by 12 months. They may fall to undetectable levels (ie, seroreversion) in the terminal stage of AIDS when the patient's immune system is severely depressed.

AIDS is caused by 2 known types of HIV. HIV type 1 (HIV-1) is found in patients with AIDS or AIDS-related complex and in asymptomatic infected individuals at high risk for AIDS. The virus is transmitted by sexual contact, by exposure to infected blood or blood products, or from an infected mother to her fetus or infant. HIV type 2 (HIV-2) infection is endemic only in West Africa, and it has been identified in individuals who had sexual relations with individuals from that geographic region. HIV-2 is similar to HIV-1 in viral morphology, overall genomic structure, and its ability to cause AIDS. Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure and are almost always detectable by 12 months. They may fall to undetectable levels (ie, seroreversion) in the terminal stage of AIDS when the patient's immune system is severely depressed.

AIDS is caused by 2 known types of HIV. HIV type 1 (HIV-1) is found in patients with AIDS or AIDS-related complex and in asymptomatic infected individuals at high risk for AIDS. The virus is transmitted by sexual contact, by exposure to infected blood or blood products, or from an infected mother to her fetus or infant. HIV type 2 (HIV-2) infection is endemic only in West Africa, and it has been identified in individuals who had sexual relations with individuals from that geographic region. HIV-2 is similar to HIV-1 in viral morphology, overall genomic structure, and its ability to cause AIDS. Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure and are almost always detectable by 12 months. They may fall to undetectable levels (ie, seroreversion) in the terminal stage of AIDS when the patient's immune system is severely depressed. Negative HIV-1/-2 antigen and antibody screening test results usually indicate absence of HIV-1 and HIV-2 infection. However, such negative results do not rule-out acute HIV infection. If acute HIV-1 or HIV-2 infection is suspected, detection of HIV RNA (HIP12 / HIV-1/HIV-2 RNA Detection, Plasma) is recommended.

AIDS is caused by 2 known types of HIV. HIV type 1 (HIV-1) is found in patients with AIDS or AIDS-related complex and in asymptomatic infected individuals at high risk for AIDS. The virus is transmitted by sexual contact, by exposure to infected blood or blood products, or from an infected mother to her fetus or infant. HIV type 2 (HIV-2) infection is endemic only in West Africa, and it has been identified in individuals who had sexual relations with individuals from that geographic region. HIV-2 is similar to HIV-1 in viral morphology, overall genomic structure, and its ability to cause AIDS. Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure and are almost always detectable by 12 months. They may fall to undetectable levels (ie, seroreversion) in the terminal stage of AIDS when the patient's immune system is severely depressed.

looks for HIV infection

What is Mycoplasma hominis? Mycoplasma hominis is a type of bacteria that naturally lives in the urogenital tract of some healthy people. It’s part of the Mycoplasma family, which are unique bacteria that lack a cell wall—making them harder to detect and treat with standard antibiotics like penicillin. In many individuals, Mycoplasma hominis is harmless. But in others, especially when it grows out of balance or spreads, it can contribute to urogenital infections, reproductive health issues, and even complications in pregnancy. Why is this test ordered? The Ureaplasma/Mycoplasma hominis test is usually ordered when someone is experiencing: Vaginal or urethral discharge Burning or pain during urination Pelvic pain Symptoms of bacterial vaginosis Infertility or recurrent pregnancy loss Signs of prostatitis in men Suspected infection after delivery or gynecologic procedures It’s also used in fertility assessments and in cases of inflammation without a clear cause. What does a positive Mycoplasma hominis result mean? A positive result means that Mycoplasma hominis DNA or culture was detected in your urogenital sample (urine, vaginal swab, semen, or urethral swab). This may indicate: Active infection or overgrowth, especially if symptoms are present Asymptomatic colonization, which may not require treatment in some cases Potential reproductive complications if found in higher amounts or in pregnancy It’s important to interpret the result in context with symptoms, other infections (like Ureaplasma or STIs), and patient history. What are the possible complications? In some people, especially those who are pregnant or immunocompromised, Mycoplasma hominis may be linked to: Pelvic inflammatory disease (PID) Chorioamnionitis (infection of the fetal membranes) Preterm labor or miscarriage Infertility or embryo implantation failure Postpartum or post-surgical infections In men, it may contribute to prostatitis or urethritis, although less commonly than in women. What to do next if your result is positive Talk to your healthcare provider Treatment decisions depend on your symptoms and health status. If you’re asymptomatic, your doctor may choose to monitor rather than treat. Consider antibiotics if indicated Mycoplasma hominis is resistant to penicillin and other beta-lactam antibiotics. If treatment is needed, your provider may prescribe tetracyclines, macrolides, or fluoroquinolones depending on the situation. Partner testing may be recommended In some cases—especially with recurrent infections or fertility issues—sexual partners may also need to be tested or treated. Retesting after treatment A follow-up test may be recommended to confirm that the infection has cleared, especially if symptoms persist or you're trying to conceive. Bottom Line Mycoplasma hominis is a bacteria that can live in the urogenital tract without causing problems—but in some people, especially those with symptoms or pregnancy concerns, it can contribute to infections and complications. A positive result doesn’t always mean you need antibiotics, but it should be discussed with your provider to determine the best next step for your health and fertility.

a sexually transmitted disease (STD)

a sexually transmitted infection (STI) caused by a parasite called Trichomonas vaginalis (TV)

A urogenital Ureaplasma NAA test reported positive or negative.